Sequential Screening for Better Hits, Faster

The Beacon platform by Bruker Cellular Analysis is a disruptive, best-in-industry technology for single B cell screening. It enables high-resolution screening of antibody-secreting B cells with throughput and timeline previously unimaginable for antibody discovery.

Our scientists at Twist Biopharma Solutions are the first to adopt this state-of-the-art technology, meaning every obstacle or challenge has been tested and optimized to provide you with all the benefits this platform offers. Days after tissue collection, the Beacon provides a rich data set about each antibody screened to identify the rare and cross-reactive antibodies ideal for clinical development. Those antibodies are sequenced and rapidly expressed in-house to advance them to characterization and developability assays.

In vivo antibody discovery in weeks instead of months?

We do that. The Beacon-based B cell screening enables high-resolution screening for ideal, rare antibodies in previously impossible timelines.